Isofol initiates a stepwise process for the continued development of its drug candidate arfolitixorin
Gothenburg, Sweden, March 6, 2023 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announces today that the company has decided to initiate a stepwise process to enable a cost-effective and risk-minimizing continued development of its drug candidate arfolitixorin. The company assesses that the planned activities, which are expected to be financed with existing funds, have the potential to bring arfolitixorin significantly closer to a market launch.The information in this press release is intended for investors. Isofol´s drug candidate arfolitixorin has shown potential to improve